Navigation Links
New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
Date:11/7/2011

ts as non-, moderate, or good responders, depending on the extent of change and the level of disease activity reached.

The RAPID3 patient-derived assessment of disease activity has been shown to correlate with disease activity score, DAS28, in patients treated with certolizumab pegol. DAS28 is defined as a clinical index of RA disease activity that combines information from swollen joints, tender joints, an acute phase response, and general health.

Previous post-hoc analyses with certolizumab pegol have demonstrated that a lack of improvement in DAS28 (greater than or equal to 1.2) by Week 12 predicts failure to achieve low disease activity at one year. The analysis presented here examined whether RAPID3 or EULAR responses at Week 12 predicted structural joint damage at one year (defined as change from baseline in modified Total Sharp Score [mTSS]) in patients treated with certolizumab pegol plus MTX or placebo plus MTX. The mTSS assesses bone erosion and joint space narrowing measured by X-ray. A smaller change in mTSS reflects less progression of joint damage.

In this post-hoc analysis, patients taking certolizumab pegol 200mg two weekly plus MTX or MTX alone in the RAPID 1 study were evaluated. RAPID 1 was a Phase III double-blind placebo-controlled trial designed to establish the efficacy and tolerability of certolizumab pegol plus MTX in the treatment of moderate to severely active RA in patients who did not adequately respond to treatment. RAPID 1 met the co-primary endpoints which were ACR20 score at Week 24 and change in mTSS at Week 52. At Week 12, patients were categorized according to good, moderate or poor based on RAPID3 or EULAR response criteria. Data were pooled for patients in each group achieving a good or moderate RAPID3 or EULAR response, and progression of joint damage was evaluated in good/moderate versus poor RAPID3 or EULAR responders.

The analysis showed that the rate of mTSS non-progressors at Week 52 was high
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
2. Rapid Fire Marketing: Medical Cannabis Management Signs Agreement with Second Non-Profit
3. Baxano Rapidly Expands Sales Force to Support Robust Demand for the iO-Flex® System
4. GNS Healthcare, Inc. Expands Senior Management Team to Leverage the Rapidly Growing Opportunities for Big Data in Healthcare Management
5. Trinity Pharma Solutions Brings SaaS Benefits to Life Sciences Industry with Rapid Access to Actionable Sales Intelligence
6. Scientific Presentations at 2011 AAPM/COMP Meeting Highlight TrueBeam® and RapidArc® Radiotherapy Systems From Varian Medical Systems
7. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
8. Al Kindy Hospital in Morocco Carries Out First RapidArc® Radiotherapy Treatments in North Africa
9. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
10. Objet to Demonstrate One-of-a-Kind, Multi-Material 3D Printing Applications at Rapid 2011
11. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, ... Global Biotechnology, Inc. for the compounding, packaging and distributing of ... in the United States . ... capable of compounding naltrexone tablets in various strengths for individual ...
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... NEW YORK, April 14, 2011 Dr. David Samadi, Vice ... at The Mount Sinai Medical Center in New York City , ... month in the British Medical Journal ( ... 1,500 of whom were screened for prostate cancer every ...
... Calif., April 14, 2011 Freedom Innovations, a ... technology lower extremity prosthetic devices, today announced a ... exclusive rights to commercialize the world,s first lower ... joints that operate synergistically.  Developed at the Vanderbilt ...
Cached Medicine Technology:Does Prostate Cancer Screening Reduce Mortality Rates? 2Does Prostate Cancer Screening Reduce Mortality Rates? 3Does Prostate Cancer Screening Reduce Mortality Rates? 4Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 2Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 3
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... 2015 Recently, Weddingshe.com has added many trendy ... announced its highest annual revenues in the past three years. ... glamorous wedding dresses. , According to the sales manager of ... promotions for them in 2015. This point can be reflected ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... has released a new blog post explaining the importance of keeping ... costs of an auto insurance policy . , Clients who ... for their vehicle insurance policies. The safety a vehicle offers from ... Because of this, drivers should always carry a first aid kit ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... in U.S., study finds , TUESDAY, April 6 (HealthDay ... of prescription sedatives, tranquilizers and other painkilling drugs has ... , Hospital stays from an unintentional overdose of opioids ... Valium and Ativan) jumped 37 percent between 1999 and ...
... ... II of III in Webinar Series on Opportunities for Improvement in Various Stages of ... ... Morehead, the human capital research firm, will host a webinar titled “When Engagement Isn’t ...
... , ... Intellidimension, Inc. a leading provider of Semantic Web infrastructure technologies announced today that ... , ... (PRWEB) April 6, 2010 -- Intellidimension, Inc. a leading provider of Semantic Web ...
... ... of search optimized patient education content for urgent care websites. These customizable pages inform ... option. Using this content helps the urgent care clinics attract patients who would otherwise ... ...
... 55 who carry an inherited mutation in the breast ... more likely to develop cancer in the breast opposite, ... breast cancer patients without these genetic defects. These findings, ... Kathleen Malone, Ph.D., and colleagues, were published online April ...
... ... innovation rooms of mySkin.com. The app empowers a skincare shopper to make an educated decision ... ... mySkin.com announces the release of its interactive skincare Facebook application , Beauty4Me. ...
Cached Medicine News:Health News:Prescription Drug Abuse Sending More to Hospitals 2Health News:Prescription Drug Abuse Sending More to Hospitals 3Health News:Morehead Presents Webinar on ,“When Engagement Isn't Enough: Retaining RNs”, 2Health News:Intellidimension Announces Semantic Web Technology Partnership with Matrikon 2Health News:Intellidimension Announces Semantic Web Technology Partnership with Matrikon 3Health News:WebForDoctors' Medical Content Pages Direct Patients to Urgent Care Centers as Alternatives to Emergency Rooms 2Health News:WebForDoctors' Medical Content Pages Direct Patients to Urgent Care Centers as Alternatives to Emergency Rooms 3Health News:Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast 2Health News:Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast 3Health News:Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast 4Health News:mySkin.com Announces Beauty4Me: An Interactive Facebook Application 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: